D-2-Hydroxyglutarate in Glioma Biology

R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis

(2021) Ying Qing et al.   MOLECULAR CELL

Oncometabolite in Cancer: Current Understanding and Challenges

(2021) Yang Liu et al.   CANCER RESEARCH

IDH Inhibitors in AML—Promise and Pitfalls

(2021) Hannah McMurry et al.   Current Hematologic Malignancy Reports

Wnt/beta-catenin and PI3K/Akt/mtor Signaling Pathways in Glioblastoma: Two main targets for drug design: A Review

(2020) Seyed Hossein Shahcheraghi et al.   CURRENT PHARMACEUTICAL DESIGN

Extracellular glutamate and IDH1R132H inhibitor promote glioma growth by boosting redox potential

(2020) Patricia D. B. Tiburcio et al.   JOURNAL OF NEURO-ONCOLOGY

Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma

(2020) Zenon Konteatis et al.   ACS Medicinal Chemistry Letters

Correlation between IDH, ATRX, and TERT promoter mutations in glioma

(2020) Shigeo Ohba et al.   Brain Tumor Pathology

Metabolic Regulation of Stem Cell Fate and Function

(2020) Suzanne N. Shapira et al.   FASEB JOURNAL

INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation.

(2020) Ingo K. Mellinghoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism

(2020) Di Yu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

mTORC2/Rac1 Pathway Predisposes Cancer Aggressiveness in IDH1-Mutated Glioma

(2020) Yang Liu et al.   Cancers

Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma

(2020) Ingo K. Mellinghoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Oncometabolites suppress DNA repair by disrupting local chromatin signalling

(2020) Parker L. Sulkowski et al.   NATURE

IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response

(2019) Felipe J. Núñez et al.   Science Translational Medicine

Phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001b in patients with recurrent or progressive IDH1 mutant gliomas.

(2019) Atsushi Natsume et al.   JOURNAL OF CLINICAL ONCOLOGY

Isocitrate dehydrogenase1 mutation reduces the pericyte coverage of microvessels in astrocytic tumours

(2019) Chao Sun et al.   JOURNAL OF NEURO-ONCOLOGY

Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease

(2019) Serena Tommasini-Ghelfi et al.   Science Advances

DNA hypermethylation in disease: mechanisms and clinical relevance

(2019) Melanie Ehrlich   Epigenetics

Friend or foe—IDH1 mutations in glioma 10 years on

(2019) L Eric Huang   CARCINOGENESIS

Blockade of glutathione metabolism in IDH1-mutated glioma

(2019) Xiaoying Tang et al.   MOLECULAR CANCER THERAPEUTICS

The Role of Glutaminase in Cancer

(2019) Brendah K. Masisi et al.   HISTOPATHOLOGY

Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin

(2019) Julia Biedermann et al.   Cancers

R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m 6 A/MYC/CEBPA Signaling

(2018) Rui Su et al.   CELL

IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity

(2018) Mohammed Khurshed et al.   FASEB JOURNAL

The role of mTOR-mediated signaling in the regulation of cellular migration

(2018) Ailsa K. Holroyd et al.   IMMUNOLOGY LETTERS

Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting

(2018) Anna Tietze et al.   JOURNAL OF NEUROSURGERY

DEPTOR at the Nexus of Cancer, Metabolism, and Immunity

(2018) Alexandre Caron et al.   PHYSIOLOGICAL REVIEWS

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

(2018) Janeta Popovici-Muller et al.   ACS Medicinal Chemistry Letters

Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate

(2018) Ovidiu C. Andronesi et al.   Nature Communications

Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2

(2018) Amir T. Fathi et al.   JAMA Oncology

Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2

(2018) Rui Ma et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma

(2018) Samuel K. McBrayer et al.   CELL

Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence

(2018) Carmen Mecca et al.   DISEASE MARKERS

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo

(2017) A Chaturvedi et al.   LEUKEMIA

Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence

(2017) Sevin Turcan et al.   NATURE GENETICS

TET-mediated active DNA demethylation: mechanism, function and beyond

(2017) Xiaoji Wu et al.   NATURE REVIEWS GENETICS

Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications

(2017) Tathiane M Malta et al.   NEURO-ONCOLOGY

2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity

(2017) Parker L. Sulkowski et al.   Science Translational Medicine

Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor

(2017) Young Shin Cho et al.   ACS Medicinal Chemistry Letters

BCAT1 controls metabolic reprogramming in activated human macrophages and is associated with inflammatory diseases

(2017) Adonia E. Papathanassiu et al.   Nature Communications

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations

(2017) Katharine Yen et al.   Cancer Discovery

TET2 in Normal and Malignant Hematopoiesis

(2017) Robert L. Bowman et al.   Cold Spring Harbor Perspectives in Medicine

A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit

(2017) Johnny Kopinja et al.   Scientific Reports

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2

(2016) Satoshi Inoue et al.   CANCER CELL

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma

(2016) Michele Ceccarelli et al.   CELL

Mitochondrial Protein Lipoylation and the 2-Oxoglutarate Dehydrogenase Complex Controls HIF1α Stability in Aerobic Conditions

(2016) Stephen P. Burr et al.   Cell Metabolism

Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase

(2016) J. Kalinina et al.   CLINICAL CANCER RESEARCH

Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120

(2016) K.C. Birendra et al.   Clinical Lymphoma Myeloma & Leukemia

TET2-mediated 5-hydroxymethylcytosine induces genetic instability and mutagenesis

(2016) Emna Mahfoudhi et al.   DNA REPAIR

Oncometabolites: Unconventional triggers of oncogenic signalling cascades

(2016) Marco Sciacovelli et al.   FREE RADICAL BIOLOGY AND MEDICINE

IDH mutation is associated with higher risk of malignant transformation in low-grade glioma

(2016) Severina Leu et al.   JOURNAL OF NEURO-ONCOLOGY

The Warburg Effect: How Does it Benefit Cancer Cells?

(2016) Maria V. Liberti et al.   TRENDS IN BIOCHEMICAL SCIENCES

The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway

(2016) Mélissa Carbonneau et al.   Nature Communications

Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion

(2015) Kensuke Tateishi et al.   CANCER CELL

2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling

(2015) Xudong Fu et al.   Cell Metabolism

Metabolic pathways promoting cancer cell survival and growth

(2015) Lindsey K. Boroughs et al.   NATURE CELL BIOLOGY

Isocitrate dehydrogenase mutations in gliomas

(2015) Matthew S. Waitkus et al.   NEURO-ONCOLOGY

Genetic alterations of DNA methylation machinery in human diseases

(2015) Tewfik Hamidi et al.   Epigenomics

Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents

(2015) Pu Wang et al.   Cell Reports

Genetic Characterization of Ten-Eleven-Translocation Methylcytosine Dioxygenase Alterations in Human Glioma

(2015) Theo F. J. Kraus et al.   Journal of Cancer

IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition

(2014) A. Kernytsky et al.   BLOOD

Mutant IDH1-Driven Cellular Transformation Increases RAD51-Mediated Homologous Recombination and Temozolomide Resistance

(2014) Shigeo Ohba et al.   CANCER RESEARCH

DEP domain-containing mTOR-interacting protein in the rat brain: Distribution of expression and potential implication

(2014) Alexandre Caron et al.   JOURNAL OF COMPARATIVE NEUROLOGY

Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation

(2014) Jinlong Shi et al.   TUMOR BIOLOGY

Suppression of TET1-Dependent DNA Demethylation Is Essential for KRAS-Mediated Transformation

(2014) Bo-Kuan Wu et al.   Cell Reports

Autophagy and oxidative stress in gliomas with IDH1 mutations

(2013) Misty R. Gilbert et al.   ACTA NEUROPATHOLOGICA

Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML

(2013) A. Chaturvedi et al.   BLOOD

Regulation and dysregulation of astrocyte activation and implications in tumor formation

(2013) Chunzhang Yang et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

The role of phosphatidylcholine and choline metabolites to cell proliferation and survival

(2013) Neale D. Ridgway   CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY

Induction of sarcomas by mutant IDH2

(2013) C. Lu et al.   GENES & DEVELOPMENT

Histone 3 Lysine 9 Trimethylation Is Differentially Associated With Isocitrate Dehydrogenase Mutations in Oligodendrogliomas and High-Grade Astrocytomas

(2013) Sriram Venneti et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells

(2013) D. Rohle et al.   SCIENCE

Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities

(2013) R. A. Cairns et al.   Cancer Discovery

Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate

(2012) Patrick S. Ward et al.   CANCER CELL

A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation

(2012) C. G. Duncan et al.   GENOME RESEARCH

IDH1 mutations inhibit multiple α-ketoglutarate-dependent dioxygenase activities in astroglioma

(2012) Ying Liu et al.   JOURNAL OF NEURO-ONCOLOGY

IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas

(2012) Tareq A. Juratli et al.   JOURNAL OF NEURO-ONCOLOGY

IDH mutation impairs histone demethylation and results in a block to cell differentiation

(2012) Chao Lu et al.   NATURE

Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation

(2012) Peppi Koivunen et al.   NATURE

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

(2012) Sevin Turcan et al.   NATURE

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas

(2012) Gang Wu et al.   NATURE GENETICS

2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas

(2012) Changho Choi et al.   NATURE MEDICINE

The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells

(2012) Tor-Christian Aase Johannessen et al.   NEURO-ONCOLOGY

Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation

(2012) Sichen Li et al.   NEURO-ONCOLOGY

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

(2012) Jay P. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

The emerging role of fumarate as an oncometabolite

(2012) Ming Yang et al.   Frontiers in Oncology

Detection of 2-Hydroxyglutarate in Formalin-Fixed Paraffin-Embedded Glioma Specimens by Gas Chromatography/Mass Spectrometry

(2011) Felix Sahm et al.   BRAIN PATHOLOGY

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

(2011) Wei Xu et al.   CANCER CELL

IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma

(2011) Qi SongTao et al.   CANCER SCIENCE

Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids

(2011) Lakshminarayan M. Iyer et al.   CELL CYCLE

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

(2011) Rasheduzzaman Chowdhury et al.   EMBO REPORTS

N6-Methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO

(2011) Guifang Jia et al.   Nature Chemical Biology

Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2

(2011) M Fernanda Amary et al.   NATURE GENETICS

Identification of additional IDH mutations associated with oncometabolite R(−)-2-hydroxyglutarate production

(2011) P S Ward et al.   ONCOGENE

Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine

(2011) S. Ito et al.   SCIENCE

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value

(2010) S. Abbas et al.   BLOOD

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

(2010) Patrick S. Ward et al.   CANCER CELL

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

(2010) Houtan Noushmehr et al.   CANCER CELL

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

(2010) Maria E. Figueroa et al.   CANCER CELL

Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas

(2010) Jefferson Pessoa Hemerly et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Glutamate and the biology of gliomas

(2010) John de Groot et al.   GLIA

DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in Glioma

(2010) Brock C. Christensen et al.   JNCI-Journal of the National Cancer Institute

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

(2010) Myunggon Ko et al.   NATURE

mTOR signaling in glioblastoma: lessons learned from bench to bedside

(2010) D. Akhavan et al.   NEURO-ONCOLOGY

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas

(2010) C. Houillier et al.   NEUROLOGY

Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species

(2010) S. Suzuki et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IDH2 Mutations in Patients with D-2-Hydroxyglutaric Aciduria

(2010) M. Kranendijk et al.   SCIENCE

Mutant Metabolic Enzymes Are at the Origin of Gliomas

(2009) H. Yan et al.   CANCER RESEARCH

DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival

(2009) Timothy R. Peterson et al.   CELL

DNA Repair in Mammalian Cells

(2009) B. Pardo et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas

(2009) S. Nobusawa et al.   CLINICAL CANCER RESEARCH

Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas

(2009) Marc Sanson et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1 

(2009) S. Zhao et al.   SCIENCE

Regulation of Neuronal Glutathione Synthesis

(2008) Koji Aoyama et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Astrocyte and Neuron Intone Through Glutamate

(2008) Chun Zhang Yang et al.   NEUROCHEMICAL RESEARCH

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE